InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Acrivon Therapeutics, Inc.

ACRV Clue Score43
United States Fiscal year ends December CIK 0001781174
$1.91 +2.14% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $1.91 −72.08% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 15 Nov 2022. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2021Operating income−16.2Net income−16.2EPS, diluted−9.32Fiscal year 2022Operating income−32.7Net income−31.2EPS, diluted−7.56Fiscal year 2023Operating income−67.1Net income−60.4EPS, diluted−2.74Fiscal year 2024Operating income−89.2Net income−80.6EPS, diluted−2.38Fiscal year 2025Operating income−84.1Net income−77.9EPS, diluted−2.02
FY2021FY2022FY2023FY2024FY2025
Operating income −16.2 −32.7 −67.1 −89.2 −84.1
Net income −16.2 −31.2 −60.4 −80.6 −77.9
Growth
EPS, diluted −9.32 −7.56 −2.74 −2.38 −2.02

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2021Operating cash flow−14.0Capital expenditure−0.2Free cash flow−14.2Fiscal year 2022Operating cash flow−30.1Capital expenditure−2.2Free cash flow−32.3Fiscal year 2023Operating cash flow−42.6Capital expenditure−1.3Free cash flow−43.9Fiscal year 2024Operating cash flow−65.7Capital expenditure−2.8Free cash flow−68.4Fiscal year 2025Operating cash flow−63.7Capital expenditure−1.7Free cash flow−65.3
FY2021FY2022FY2023FY2024FY2025
Operating cash flow −14.0 −30.1 −42.6 −65.7 −63.7
Capital expenditure −0.2 −2.2 −1.3 −2.8 −1.7
Free cash flow −14.2 −32.3 −43.9 −68.4 −65.3
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2021Cash99.6Shareholders’ equity−23.8Fiscal year 2022Cash29.5Shareholders’ equity170.5Fiscal year 2023Cash36.0Shareholders’ equity121.2Fiscal year 2024Cash39.8Shareholders’ equity176.8Fiscal year 2025Cash41.5Shareholders’ equity112.5
FY2021FY2022FY2023FY2024FY2025
Cash 99.6 29.5 36.0 39.8 41.5
Shareholders’ equity −23.8 170.5 121.2 176.8 112.5

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Returns
n/a −18.3% −49.8% −45.6% −69.2%
−15.2% −17.2% −43.7% −41.0% −60.1%
Balance and payout
7.4% 5.9% 12.3% 10.1% 13.3%